These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 8900891)

  • 1. [Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring].
    Henze T
    Fortschr Neurol Psychiatr; 1996 Mar; 64(3):110-21. PubMed ID: 8900891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial.
    Sieb JP; Köhler W
    Clin Neurol Neurosurg; 2010 Nov; 112(9):781-4. PubMed ID: 20663605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
    Henze T; Nenner M; Michaelis HC
    J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis.
    Punga AR; Sawada M; Stålberg EV
    Muscle Nerve; 2008 Mar; 37(3):300-7. PubMed ID: 18069667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
    Schumm F; Gaertner HJ; Wiatr G; Dichgans J
    Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
    Tripathi M; Kaushik S; Dubey P
    J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identical kinetics of human erythrocyte and muscle acetylcholinesterase with respect to carbamate pre-treatment, residual activity upon soman challenge and spontaneous reactivation after withdrawal of the inhibitors.
    Herkert NM; Eckert S; Eyer P; Bumm R; Weber G; Thiermann H; Worek F
    Toxicology; 2008 Apr; 246(2-3):188-92. PubMed ID: 18304715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
    Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
    Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myasthenia gravis pseudoparalytica. Clinical picture, pathogenesis, therapy].
    Kunze K
    Med Klin; 1973 Jun; 68(22):723-30. PubMed ID: 4715780
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro kinetic interactions of pyridostigmine, physostigmine and soman with erythrocyte and muscle acetylcholinesterase from different species.
    Herkert NM; Thiermann H; Worek F
    Toxicol Lett; 2011 Sep; 206(1):41-6. PubMed ID: 21414391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of cholinesterase inhibitors.
    Aquilonius SM; Hartvig P
    Clin Pharmacokinet; 1986; 11(3):236-49. PubMed ID: 3524957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary vasospasm secondary to hypercholinergic crisis: an iatrogenic cause of acute myocardial infarction in myasthenia gravis.
    Comerci G; Buffon A; Biondi-Zoccai GG; Ramazzotti V; Romagnoli E; Savino M; Rebuzzi AG; Biasucci LM; Loperfido F; Crea F
    Int J Cardiol; 2005 Sep; 103(3):335-7. PubMed ID: 16098399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
    Musilek K; Komloova M; Zavadova V; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K; Jung YS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1763-6. PubMed ID: 20138518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
    Kupersmith MJ; Ying G
    Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing of antidotes for organophosphorus compounds: experimental procedures and clinical reality.
    Eyer P; Szinicz L; Thiermann H; Worek F; Zilker T
    Toxicology; 2007 Apr; 233(1-3):108-19. PubMed ID: 17010492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myasthenia gravis in Santo Tomás Hospital 1990-1997].
    Frago G; Gracia F; Chang E; Andrade Alegre R
    Rev Med Panama; 1998 Sep; 23(2):15-9. PubMed ID: 11214554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery from myasthenic crisis after use of IVIG therapy.
    Jain K; Passi GR; Rajguru M; Athle S; Gandhi DM
    Indian Pediatr; 1998 Sep; 35(9):901-3. PubMed ID: 10216601
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.
    Yamamoto K; Sawada Y; Iga T
    J Pharmacokinet Biopharm; 1996 Aug; 24(4):327-48. PubMed ID: 9044164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Integrated traditional Chinese and Western medicine in treating 31 cases of myasthenia gravis].
    Chen SL; Liu XY; Zhang WX
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):964-7. PubMed ID: 18782544
    [No Abstract]   [Full Text] [Related]  

  • 20. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase.
    Haigh JR; Johnston SR; Peppernay A; Mattern PJ; Garcia GE; Doctor BP; Gordon RK; Aisen PS
    Chem Biol Interact; 2008 Sep; 175(1-3):380-6. PubMed ID: 18572153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.